Other languages 89bio, Inc.

Equities

ETNB

US2825591033

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
7.52 ^USD	+0.79%		-6.12%	-32.68%

Jul. 01	89bio, Inc.(NasdaqGM:ETNB) added to Russell Small Cap Comp Value Index	CI
Jul. 01	89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 3000E Growth Index	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis at EASL International Liver Congress	May. 22
89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis	May. 14
89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
89bio, Inc. Appoints Martin Babler to Its Board of Directors	Apr. 17
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	Apr. 03
Sector Update: Health Care Stocks Gain Wednesday Afternoon	Mar. 27
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	Mar. 27
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	Mar. 27
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	Mar. 12
Top Premarket Gainers	Mar. 04
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29
89bio Insider Sold Shares Worth $560,000, According to a Recent SEC Filing	Jan. 03
89bio Prices Upsized $150 Million Offering of Common Shares, Pre-Funded Warrants	Dec. 07
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Dec. 07
89bio Launches $125 Million Offering of Common Shares, Pre-Funded Warrants	Dec. 07
Sector Update: Health Care Stocks Rise Late Afternoon	Dec. 04
Sector Update: Health Care Stocks Rise Monday Afternoon	Dec. 04
89bio Share Rise on Advance Into Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis	Dec. 04
89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis	Dec. 04
89bio Sees 'Positive' Long-Term Results From Phase 2b Study of Pegozafermin to Treat Nonalcoholic Steatohepatitis	Nov. 27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages 89bio, Inc.

Equities

ETNB

US2825591033

Other languages

Filters